SAKK 67/20 Open-label single-stage phase 1B study of the new micellar docetaxel compound Docecal in patients with advanced castra-tion-resistant prostate cancer
May 28, 2021
Background:
Docetaxel, a semi-synthetic analogue of paclitaxel, is one of the most widely used human anti-cancer agents. Docetaxel and paclitaxel belong to a group of cytotoxic agents called tax-anes. Docetaxel has been marketed worldwide by Sanofi-...
Clinical Studies -
May 28, 2021 - Feb 1, 2024
Completed
Project leader: Fischer Stefanie
Members: Sakic Miranda, Quinter Janine
more
